Biora Therapeutics, Inc. (BIOR)
USD 0.22
(0.0%)
USD 0.22
(0.0%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -114.05 Million USD | -12.55% |
| 2022 | -37.35 Million USD | 7.09% |
| 2021 | -164.56 Million USD | 67.38% |
| 2020 | -106.18 Million USD | -46.54% |
| 2019 | -135.44 Million USD | -22.54% |
| 2018 | -110.16 Million USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | -15.67 Million USD | 664.43% |
| 2024 Q1 | -15.51 Million USD | 90.71% |
| 2023 Q2 | -14.77 Million USD | 4.55% |
| 2023 FY | - USD | -12.55% |
| 2023 Q3 | -23.32 Million USD | -57.86% |
| 2023 Q1 | -15.47 Million USD | 3.16% |
| 2023 Q4 | -13.22 Million USD | 43.28% |
| 2022 Q3 | -13.78 Million USD | -67.09% |
| 2022 Q2 | -8.25 Million USD | 71.13% |
| 2022 Q1 | -28.57 Million USD | -201.4% |
| 2022 FY | - USD | 7.09% |
| 2022 Q4 | -15.98 Million USD | -15.94% |
| 2021 FY | - USD | 67.38% |
| 2021 Q3 | -29.99 Million USD | 8.42% |
| 2021 Q4 | 28.18 Million USD | 193.95% |
| 2021 Q2 | -32.75 Million USD | -8.65% |
| 2021 Q1 | -30.14 Million USD | 41.32% |
| 2020 Q2 | -45.92 Million USD | 9.69% |
| 2020 Q1 | -50.84 Million USD | -11.68% |
| 2020 FY | - USD | -46.54% |
| 2020 Q4 | -51.37 Million USD | -18.61% |
| 2020 Q3 | -43.31 Million USD | 5.68% |
| 2019 Q4 | -45.52 Million USD | 15.16% |
| 2019 Q2 | -13.37 Million USD | 33.77% |
| 2019 Q1 | -20.19 Million USD | 69.16% |
| 2019 FY | - USD | -22.54% |
| 2019 Q3 | -53.66 Million USD | -301.17% |
| 2018 Q4 | -65.48 Million USD | 0.0% |
| 2018 FY | - USD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| America Great Health | -447.29 Thousand USD | -25398.779% |
| Ampio Pharmaceuticals, Inc. | - USD | Infinity% |
| Aridis Pharmaceuticals, Inc. | -29.5 Million USD | -286.545% |
| Bio-Path Holdings, Inc. | -15.76 Million USD | -623.647% |
| Better Therapeutics, Inc. | -38.26 Million USD | -198.087% |
| Calithera Biosciences, Inc. | -38.26 Million USD | -198.064% |
| Comera Life Sciences Holdings, Inc. | -17.88 Million USD | -537.651% |
| Gene Biotherapeutics, Inc. | - USD | Infinity% |
| eFFECTOR Therapeutics, Inc. | -33.73 Million USD | -238.108% |
| Eloxx Pharmaceuticals, Inc. | -33.37 Million USD | -241.755% |
| Evelo Biosciences, Inc. | -106.34 Million USD | -7.249% |
| Evolutionary Genomics, Inc. | -913.47 Thousand USD | -12385.755% |
| Finch Therapeutics Group, Inc. | -32.48 Million USD | -251.13% |
| Galera Therapeutics, Inc. | -46.69 Million USD | -144.269% |
| Innovation1 Biotech Inc. | -5.68 Million USD | -1906.669% |
| Kiromic BioPharma, Inc. | -16.3 Million USD | -599.666% |
| Molecular Templates, Inc. | 1.43 Million USD | 8075.804% |
| Navidea Biopharmaceuticals, Inc. | -13.87 Million USD | -722.005% |
| NexImmune, Inc. | -28.16 Million USD | -304.913% |
| Orgenesis Inc. | -60.71 Million USD | -87.842% |
| Panbela Therapeutics, Inc. | -51.29 Million USD | -122.353% |
| Point of Care Nano-Technology, Inc. | -73.41 Thousand USD | -155253.057% |
| PaxMedica, Inc. Common Stock | -16.14 Million USD | -606.424% |
| Scopus BioPharma Inc. | -11.71 Million USD | -873.726% |
| Sorrento Therapeutics, Inc. | -539.92 Million USD | 78.876% |
| Statera Biopharma, Inc. | 38.93 Million USD | 392.935% |
| TRACON Pharmaceuticals, Inc. | -6.88 Million USD | -1556.798% |
| Trevena, Inc. | -35.28 Million USD | -223.209% |
| Vaxxinity, Inc. | -56.05 Thousand USD | -203382.543% |
| Vaccinex, Inc. | -19.74 Million USD | -477.547% |
| Vicapsys Life Sciences, Inc. | -1.04 Million USD | -10793.639% |
| Viracta Therapeutics, Inc. | -46.86 Million USD | -143.383% |
| ZIVO Bioscience, Inc. | -7.26 Million USD | -1470.34% |